NR4A1 and breast carcinoma: In a subsequent publication, Symmans and co-authors have demonstrated that the RCB is a prognostic marker independent from the type of primary chemotherapeutic regime and significant differences have been described between RCB classes among hormone receptor positive (ER+ and/or PR+, HER2-), HER-2 positive (hormone receptor positive or negative) and triple negative (ER-, PR, HER2-) breast cancer cases [32].